Supplementary Figure 1: Dose validation of secondary pharmaceutical agents in combination with Resminostat against HCC. Sc-1 (1 μM, 5 μM, 10 μM), Cisplatin (5 μM, 10 μM), Doxorubicin (0.5 μM, 1 μM), DZNep (5 μM, 10 μM, 20 μM) and GSK343 (2 nM, 4 nM, 7 nM) were used in dose validation in HCC cells examining their optimised dose for anti-proliferative effect (n = 3). Proliferation was measured with FluoroFire-Blue ProViaTox assay and presented as fold change compared to control (untreated cells).
<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Sequence</th>
</tr>
</thead>
</table>
| β-Actin (ACTβ) | Forward: 5'-CCTTGCACATGCCGGAG-3'  
                Reverse: 5'-GCACAGAGCCTCGGAAATTA-3' |
| HDAC 1      | Forward: 5'-CATCTCCTCACTATGGGCTT-3'  
                Reverse: 5'-GACGGGGATGTTGGAAATTA-3' |
| HDAC 2      | Forward: 5'-CAGCAAGTTATGGGTACATGC-3'  
                Reverse: 5'-CCATGGCGTACAGTCAAGGA-3' |
| HDAC 3      | Forward: 5'-GTGTGTTCAGTGGGTTGCTC-3'  
                Reverse: 5'-GAGAGTCAGGCACCAACATTA-3' |
| HDAC 6      | Forward: 5'-TCCAAAGCCACATTTGAGTA-3'  
                Reverse: 5'-CACAGTTCACTTCCGACCAG-3' |
| HDAC 8      | Forward: 5'-GAGTCCATTGATCGCTTCC-3'  
                Reverse: 5'-ATTTTGGGAGGAGGAGGCTA-3' |
| Caspase 3   | Forward: 5'-TCTGGTTTTCGGTGGTG-3'  
                Reverse: 5'-TGCCCAGCTTTTCAAAATTC-3' |
| Caspase 7   | Forward: 5'-TGCCCAGCTTTTCAAAATTC-3'  
                Reverse: 5'-TCAGTGGATGCTAAGCCAGA-3' |
| Caspase 8   | Forward: 5'-CCAGGATGCTTCCAACACT-3'  
                Reverse: 5'-CGGAATGTAGTCCAGGCTA-3' |
| Caspase 9   | Forward: 5'-CCAGACATTTGAGTGGGACAT-3'  
                Reverse: 5'-ATCTCGGCAAGATTTACATG-3' |
| BCL-2       | Forward: 5'-CGTACAGTTCCCAAAGAGCA-3'  
                Reverse: 5'-ATGTGCTGTTGGGACGTCA-3' |
| BAX (BCL2L4) | Forward: 5'-GGAGGGAGCTTCCAAATGTCCAG-3'  
                Reverse: 5'-TCTGACGCGAACCTTCAACTG-3' |
| BIM (BCL2L11) | Forward: 5'-CCCTCCTTGGCATAGTACAAGCG-3'  
                 Reverse: 5'-CCAGGGCCTTCAACACTATC-3' |
| BAD (BCL2L8) | Forward: 5'-GGTACGAGCTCTTGAGGACAT-3'  
                Reverse: 5'-GGCTCGGCAAGCAATCACT-3' |
| Cyclin D1 (CCND1) | Forward: 5'-TGAGGCCGCTTCCGACCAG-3'  
                 Reverse: 5'-GACCTTGTCGGCCCACTTG-3' |
| P21 (CDKN1A) | Forward: 5'-GCCATTAGCGCAATCAGAAT-3'  
                 Reverse: 5'-ACCGAGGCAATCATCAGAAGAG-3' |
| P27 (CDKN1B) | Forward: 5'-ACAGAGTGGTCCATTTCCATAGA-3'  
                 Reverse: 5'-GCGTCCGCAAGAGACTCAGA-3' |
| TNFα        | Forward: 5'-AGATGATGCTATCAGCTGGG-3'  
                Reverse: 5'-CAGCGTCTTCTCTCTCTGTG-3' |
| VEGF        | Forward: 5'-CACACAGATTGGCTTAAAGA-3'  
                Reverse: 5'-AGGGACAGGAAATCATCAAGAAG-3' |
| Leptin      | Forward: 5'-GACTTTTTTGATGGGAGCAGA-3'  
                Reverse: 5'-GAGGAAATCGCAGGCCGCC-3' |
| IL-10       | Forward: 5'-GCCACCCCTGATGCTCTCGTT-3'  
                Reverse: 5'-GTGGAGGCAATGTAAGCGAC-3' |
| STAT3       | Forward: 5'-GGCCATCCTAGCTTAAAATCA-3'  
                Reverse: 5'-GTCTCTCCCTCCGCTGCT-3' |
| P16 (CDKN2A) | Forward: 5'-GGTGCGGTTAGATGGTCCG-3'  
                Reverse: 5'-CCCAACACGACCAGAATAGTA-3' |
| EZH2        | Forward: 5'-GGACGCTGCGAGGAGCAG-3'  
                Reverse: 5'-GGGCTGCACTGCTGGAGCAG-3' |
| ZFP64       | Forward: 5'-GGTACGAGCTCTTGAGGACAT-3'  
                Reverse: 5'-GGCTCGGCAAGCAATCACT-3' |
| HSP90       | Forward: 5'-CAATGACATCAAATCAGGCGCA-3'  
                Reverse: 5'-CCTGTCGCTTCTGGCTGT-3' |
| P65 (RELA)  | Forward: 5'-TCTTTCTTTCTCATTCCAGG-3'  
                Reverse: 5'-ACCCCTCCCTACGCAGAC-3' |